Lilly's EloraTZP shows stronger weight-loss results than Zepbound
Eli Lilly reported stronger weight-loss results for experimental EloraTZP compared to tirzepatide alone. Shares of LLY traded down approximately 0.8%.
Eli Lilly NYSE:LLY, the obesity, diabetes and pharmaceutical company, said experimental EloraTZP produced stronger weight-loss results than tirzepatide alone, while shares traded around $1,148.00, down approximately 0.8%, at 1.10pm ET on Thursday, October 1. The valuation picture shows shares 2…